# A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

> **NCT07673744** · PHASE2 · RECRUITING · sponsor: **TG Therapeutics, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** Ublituximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07673744
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673744, "A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07673744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*